stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) EBITDA
Roivant Sciences Ltd.'s EBITDA for fiscal 2026 was −$511.7M, compared with −$989.2M in fiscal 2025. Over the twelve months to 30 June 2026 it was −$593.3M. Over the past ten years it has ranged from −$1.3B (fiscal 2022) to $4.5B (fiscal 2024); the current reading is higher than 71% of that period. Roivant Sciences Ltd. ranks 585th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | −$511.7M | — |
| FY2025 | −$989.2M | — |
| FY2024 | $4.5B | — |
| FY2023 | −$1.2B | — |
| FY2022 | −$1.3B | — |
| FY2021 | −$1.1B | — |
| FY2020 | −$454.9K | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$365.4M | — |
| Mar 2026 | $415.9M | — |
| Dec 2025 | −$338.5M | — |
| Sep 2025 | −$305.3M | — |
| 21 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| RPRX Royalty Pharma PLC compare | $1.5B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.4B |
| GMAB Genmab A/S Sponsored ADR compare | $1.2B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| INCY Incyte Corporation compare | $724.9M |
| INSM Insmed, Inc. compare | −$531.4M |
| ROIV Roivant Sciences Ltd. | −$593.3M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.1B |
| RVMD Revolution Medicines, Inc. compare | −$1.6B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement